CARTESIAN THERAPEUTICS INC
RNACNASDAQ🏆 #2879 by market capUS Equity
$692.36▲ $37.11 (+5.36%)
Simulated price1h—
24h▲ 5.4%
7d▲ 8191.7%
14d▲ 9281.6%
30d▲ 7993.0%
1y▲ 5873.8%
🏦Market Cap
$260M
Small Cap
📈Revenue Growth (YoY)
-94.9%
Declining
📊Gross Margin
—
💵FCF Margin
422.1%
Strong
⚖️P/S Ratio
147.6x
Expensive
Otter Score
65
Fair
Trading Snapshot
- Day Range
- $681.72 – $695.32
- 52-Week Range
- $5.60 – $12.25
- Volume
- $5.47B
- Avg Volume
- $7.01B
- Shares Outstanding
- 29.4M
- Next Earnings
- Sep 3, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $461,602
- P/E Ratio
- —
- P/S Ratio
- 147.6x
- EPS (TTM)
- $-5.80
- Dividend Yield
- —
Why Investors Own RNAC
- ✓High-growth profile — revenue up -7.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 60% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$2M▼ −10.7% YoY
Gross Margin (TTM)
59.5%▲ +3.4% YoY
Operating Income (TTM)
$425,830▼ −10.7% YoY
Free Cash Flow (TTM)
$348,406▼ −10.7% YoY
About CARTESIAN THERAPEUTICS INC
A company profile for CARTESIAN THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
65/100
Analyst Price Target
ⓘAverage Target
$754.00
▲ +8.9% Upside
High Target$928.74
Low Target$621.10
Based on 39 analysts
Latest News & Updates
🚀
CNBC·2h ago
CARTESIAN THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift RNAC price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
CARTESIAN THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.